AI COMMAND CENTER · OPERATIONAL
PHASE PRE-CLINICAL
PATENTS 3 FAMILIES
HORIZON 2038+
Agent Mode
Dense Body Platform
Non-replicating · No DNA · Whole-antigen
Program Status
EXIST Funding✓
IP Coverage2038+
Pre-clinical75%
Phase 1a INDPrep
ACTIVE CONTEXT: SCIENTIFIC ADVISOR HCMV · TRANSPLANT CONGENITAL CMV LEGALLY SCOPED
DI
DENSE IMMUNE AI · SCIENTIFIC ADVISOR
**Dense Immune Command Center** — online. I'm your dedicated AI advisor, scoped precisely to Dense Immune's validated program. Current capabilities in this session: → **Scientific Advisor** — Dense Body immunology, HCMV T-cell biology, platform differentiation → **Investor Relations** — institutional-grade narrative, legally scoped FOMO → **Regulatory Strategy** — EMA/PEI/FDA pathway, CTA/IND readiness → **Protocol Design** — Phase 1a/1b through Phase 2/3 architecture → **Literature Synthesis** — paper analysis, whole-antigen argument building Select a mode in the sidebar or ask directly. What do you need?
DI
Program Metrics
Indications 2
Dev. cost mult. 1.4×
Patent families 3
IP horizon 2038+
Platform Dense Body
Target Populations
HSCT/yr (EU+US) ~75K
SOT/yr (EU+US) ~140K
cCMV births/yr ~40K
CMV seroprevalence 40–80%
Partners
Academic UMC · SLS
CDMO Intravacc
Funding EXIST ✓
Stage Pre-IND
Legal Guardrails
All outputs scoped to:

✓ HCMV · Transplant (HSCT/SOT)
✓ Congenital CMV

✗ No off-label applications
✗ No forward-looking guarantees
✗ No unpatented use cases